The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study

We have investigated the interrelationships of plasma PAI-1 activity, the PAI-1 4G/5G polymorphism and risk of myocardial infarction (MI) in the ECTIM study, a case-control study of MI based in Belfast, Lille, Strasbourg and Toulouse. Mean PAI-1 levels in cases were similar across all centres but in controls, levels in the French centres were significantly higher. Only in Belfast were PAIl1 levels higher in cases (11.7 AU/ml) than controls (10.5 AU/ml). The PAI-1 4G allele frequency was similar in cases and controls (0.55 and 0.54). In all groups, 4G homozygotes had the highest mean plasma PAI-1 level (4G4G vs 5G5G; cases overall: 14.2 vs 12.1AU/ml; controls overall: 15.0 vs 12.6AU/ml), with the heterozygotes generally intermediate. The data from Belfast are consistent with the literature implicating PAI-1 level as an MI risk factor. In ECTIM, the PAI-1 4G/5G polymorphism is not a genetic risk factor for MI but is associated with PAI-1 activity. Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk.

[1]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[2]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[3]  L. Guize,et al.  Relationship between plasminogen activator inhibitor activity and menopausal status , 1990 .

[4]  M. Blombäck,et al.  Haemostatic function in myocardial infarction. , 1986, British heart journal.

[5]  T. Lindahl,et al.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. , 1990, The Biochemical journal.

[6]  B. Bennett,et al.  Distribution of plasminogen activator inhibitor (PAI-1) in tissues. , 1991, Journal of clinical pathology.

[7]  T. Gelehrter,et al.  Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. , 1989, Molecular endocrinology.

[8]  A. Evans,et al.  A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  F. Werf,et al.  Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.

[10]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[11]  M. Fisher,et al.  ALTERED COAGULATION IN CEREBRAL ISCHEMIA PATIENTS , 1987, Thrombosis and Haemostasis.

[12]  A. Henney,et al.  The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. , 1993, The Journal of biological chemistry.

[13]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  M. Alessi,et al.  Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol , 1985, Thrombosis and Haemostasis.

[15]  M. Fisher,et al.  Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. , 1990, Archives of neurology.

[16]  T. Nilsson,et al.  Defective fibrinolysis in survivors of myocardial infarction. , 1984, International Journal of Cardiology.

[17]  B. Bennett,et al.  Plasminogen activator inhibitor (PAI‐1) in plasma and platelets , 1988, British journal of haematology.

[18]  D. Dichek,et al.  Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. , 1989 .

[19]  M. Alessi,et al.  Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis , 1987, Thrombosis and Haemostasis.

[20]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[21]  F. España,et al.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. , 1988, British heart journal.

[22]  D. Loskutoff.  Regulation of PAI-1 gene expression , 1991 .

[23]  J. Yudkin,et al.  Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene , 1995, Diabetes.

[24]  D. Ginsburg,et al.  Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1. , 1989, Gene.

[25]  B. Risberg,et al.  Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. , 1988, Thrombosis research.

[26]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[27]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[28]  T. Saldeen,et al.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. , 1987, Journal of the American College of Cardiology.

[29]  L. Lund,et al.  The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene , 1988 .

[30]  R. Lebo,et al.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.

[31]  T. Gelehrter,et al.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[32]  B. Risberg,et al.  The Effect of Va rious Anticoagulant/Anti platelet Mixtures on Determination of Plasminogen Activator Inhibitor, Platelet Proteins and Hemostasis Farameters , 1989, Thrombosis and Haemostasis.

[33]  F. Castellino.  Biochemistry of Human Plasminogen , 1984, Seminars in thrombosis and hemostasis.

[34]  K. Huber,et al.  Circadian Fluctuations of Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma of Patients with Unstable Coronary Artery Disease and Acute Myocardial Infarction , 1988, Thrombosis and Haemostasis.

[35]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[36]  A. Haeberli,et al.  Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias , 1982 .

[37]  H. Ohlin,et al.  Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. , 1987, Thrombosis research.

[38]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.

[39]  T. Gelehrter,et al.  Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. , 1989, Molecular endocrinology.

[40]  E. Koay,et al.  Altered Fibrinolysis in DVT: Influence of Site of Sampling , 1988, Thrombosis and Haemostasis.

[41]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.

[42]  P. Bosma,et al.  Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. , 1988, The Journal of biological chemistry.

[43]  C. Hack,et al.  PAI-1 Synthesis in the Human Hepatoma Cell Line Hep G2 Is Increased by Cytokines - Evidence that the Liver Contributes to Acute Phase Behaviour of PAI-1 , 1991, Thrombosis and Haemostasis.

[44]  E. Kruithof,et al.  Studies on the Release of a Plasminogen Activator Inhibitor by Human Platelets , 1986, Thrombosis and Haemostasis.

[45]  Y. Takada,et al.  Plasma levels of t-PA free PAI-1 and a complex of t-PA with PAI-1 in human males and females at various ages. , 1989, Thrombosis research.